Lipocalin-2 and Calprotectin As Stool Biomarkers for Predicting Necrotizing Enterocolitis in Premature Neonates

Overview

Journal Pediatr Res

Specialties Biology
Pediatrics

Date 2021 Sep 1

PMID 34465872

Citations 10

Authors

Marie-Pier Thibault

Eric Tremblay

Chantal Horth

Aube Fournier-Morin

David Grynspan

Corentin Babakissa

Emile Levy

Emanuela Ferretti

Valerie Bertelle

Jean-Francois Beaulieu

Affiliations

Soon will be listed here.

Abstract

Background: Necrotizing enterocolitis (NEC) is a major challenge for premature infants in neonatal intensive care units and efforts toward the search for indicators that could be used to predict the development of the disease have given limited results until now.

Methods: In this study, stools from 132 very low birth weight infants were collected daily in the context of a multi-center prospective study aimed at investigating the potential of fecal biomarkers for NEC prediction. Eight infants (~6%) received a stage 3 NEC diagnosis. Their stools collected up to 10 days before diagnosis were included and matched with 14 non-NEC controls and tested by ELISA for the quantitation of eight biomarkers.

Results: Biomarkers were evaluated in all available stool samples leading to the identification of lipocalin-2 and calprotectin as the two most reliable predicting markers over the 10-day period prior to NEC development. Pooling the data for each infant confirmed the significance of lipocalin-2 and calprotectin, individually and in combination 1 week in advance of the NEC clinical diagnosis.

Conclusions: The lipocalin-2 and calprotectin tandem represents a significant biomarker signature for predicting NEC development. Although not yet fulfilling the "perfect biomarker" criteria, it represents a first step toward it.

Impact: Stool biomarkers can be used to predict NEC development in very low birth weight infants more than a week before the diagnosis. LCN2 was identified as a new robust biomarker for predicting NEC development, which used in conjunction with CALPRO, allows the identification of more than half of the cases that will develop NEC in very low birth weight infants. Combining more stool markers with the LCN2/CALPRO tandem such as PGE2 can further improve the algorithm for the prediction of NEC development.

Citing Articles

HIF-1α Pathway Orchestration by LCN2: A Key Player in Hypoxia-Mediated Colitis Exacerbation.

Yang Y, Yan F, Shi P, Yang L, Cui D Inflammation. 2024; 47(4):1491-1519.

PMID: 38819583 DOI: 10.1007/s10753-024-01990-y.

Iron homeostasis and post-hemorrhagic hydrocephalus: a review.

Pan S, Hale A, Lemieux M, Raval D, Garton T, Sadler B Front Neurol. 2024; 14:1287559.

PMID: 38283681 PMC: 10811254. DOI: 10.3389/fneur.2023.1287559.

Proteomics identifies lipocalin-2 in neonatal inflammation associated with cerebrovascular alteration in mice and preterm infants.

Gravina G, Ardalan M, Chumak T, Nilsson A, Ek J, Danielsson H iScience. 2023; 26(7):107217.

PMID: 37496672 PMC: 10366453. DOI: 10.1016/j.isci.2023.107217.

Noninvasive Fecal Cytokine and Microbiota Profiles Predict Commencement of Necrotizing Enterocolitis in a Proof-of-Concept Study.

Zenner C, Chalklen L, Adjei H, Dalby M, Mitra S, Cornwell E Gastro Hep Adv. 2023; 2(5):666-675.

PMID: 37469521 PMC: 10352139. DOI: 10.1016/j.gastha.2023.03.003.

Fecal and Urinary Adipokines as Disease Biomarkers.

Tews H, Elger T, Grewal T, Weidlich S, Vitali F, Buechler C Biomedicines. 2023; 11(4).

PMID: 37189804 PMC: 10135691. DOI: 10.3390/biomedicines11041186.

References

Neu J, Walker W . Necrotizing enterocolitis. N Engl J Med. 2011; 364(3):255-64. PMC: 3628622. DOI: 10.1056/NEJMra1005408. View

Henry M, Moss R . Necrotizing enterocolitis. Annu Rev Med. 2008; 60:111-24. DOI: 10.1146/annurev.med.60.050207.092824. View

Heida F, Stolwijk L, Loos M, van den Ende S, Onland W, van den Dungen F . Increased incidence of necrotizing enterocolitis in the Netherlands after implementation of the new Dutch guideline for active treatment in extremely preterm infants: Results from three academic referral centers. J Pediatr Surg. 2016; 52(2):273-276. DOI: 10.1016/j.jpedsurg.2016.11.024. View

Nino D, Sodhi C, Hackam D . Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nat Rev Gastroenterol Hepatol. 2016; 13(10):590-600. PMC: 5124124. DOI: 10.1038/nrgastro.2016.119. View

Fitzgibbons S, Ching Y, Yu D, Carpenter J, Kenny M, Weldon C . Mortality of necrotizing enterocolitis expressed by birth weight categories. J Pediatr Surg. 2009; 44(6):1072-5. DOI: 10.1016/j.jpedsurg.2009.02.013. View

Thyoka M, De Coppi P, Eaton S, Khoo K, Hall N, Curry J . Advanced necrotizing enterocolitis part 1: mortality. Eur J Pediatr Surg. 2012; 22(1):8-12. DOI: 10.1055/s-0032-1306263. View

Jones I, Hall N . Contemporary Outcomes for Infants with Necrotizing Enterocolitis-A Systematic Review. J Pediatr. 2020; 220:86-92.e3. DOI: 10.1016/j.jpeds.2019.11.011. View

Bazacliu C, Neu J . Necrotizing Enterocolitis: Long Term Complications. Curr Pediatr Rev. 2019; 15(2):115-124. DOI: 10.2174/1573396315666190312093119. View

Huda S, Chaudhery S, Ibrahim H, Pramanik A . Neonatal necrotizing enterocolitis: Clinical challenges, pathophysiology and management. Pathophysiology. 2014; 21(1):3-12. DOI: 10.1016/j.pathophys.2013.11.009. View

10.

Pike K, Brocklehurst P, Jones D, Kenyon S, Salt A, Taylor D . Outcomes at 7 years for babies who developed neonatal necrotising enterocolitis: the ORACLE Children Study. Arch Dis Child Fetal Neonatal Ed. 2012; 97(5):F318-22. DOI: 10.1136/fetalneonatal-2011-300244. View

11.

Eaton S, Rees C, Hall N . Current Research on the Epidemiology, Pathogenesis, and Management of Necrotizing Enterocolitis. Neonatology. 2017; 111(4):423-430. DOI: 10.1159/000458462. View

12.

Bazacliu C, Neu J . Pathophysiology of Necrotizing Enterocolitis: An Update. Curr Pediatr Rev. 2018; 15(2):68-87. DOI: 10.2174/1573396314666181102123030. View

13.

Samuels N, van de Graaf R, de Jonge R, Reiss I, Vermeulen M . Risk factors for necrotizing enterocolitis in neonates: a systematic review of prognostic studies. BMC Pediatr. 2017; 17(1):105. PMC: 5391569. DOI: 10.1186/s12887-017-0847-3. View

14.

Berkhout D, Klaassen P, Niemarkt H, de Boode W, Cossey V, van Goudoever J . Risk Factors for Necrotizing Enterocolitis: A Prospective Multicenter Case-Control Study. Neonatology. 2018; 114(3):277-284. DOI: 10.1159/000489677. View

15.

Cho S, Berger P, Nold-Petry C, Nold M . The immunological landscape in necrotising enterocolitis. Expert Rev Mol Med. 2016; 18:e12. PMC: 5001507. DOI: 10.1017/erm.2016.13. View

16.

Bell M, TERNBERG J, Feigin R, Keating J, Marshall R, Barton L . Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978; 187(1):1-7. PMC: 1396409. DOI: 10.1097/00000658-197801000-00001. View

17.

Gilfillan M, Bhandari V . Biomarkers for the diagnosis of neonatal sepsis and necrotizing enterocolitis: Clinical practice guidelines. Early Hum Dev. 2017; 105:25-33. DOI: 10.1016/j.earlhumdev.2016.12.002. View

18.

Gephart S, Gordon P, Penn A, Gregory K, Swanson J, Maheshwari A . Changing the paradigm of defining, detecting, and diagnosing NEC: Perspectives on Bell's stages and biomarkers for NEC. Semin Pediatr Surg. 2017; 27(1):3-10. DOI: 10.1053/j.sempedsurg.2017.11.002. View

19.

Wang K, Tao G, Sylvester K . Recent Advances in Prevention and Therapies for Clinical or Experimental Necrotizing Enterocolitis. Dig Dis Sci. 2019; 64(11):3078-3085. DOI: 10.1007/s10620-019-05618-2. View

20.

Ng P, Ma T, Lam H . The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2015; 100(5):F448-52. DOI: 10.1136/archdischild-2014-307656. View